EBS

As of October 2026, Emergent BioSolutions' stock decreased by 15.40% in the last three months and 30.01% over the last 12 months, though it increased by 11.64% in the past month. In August 2026, shares dropped significantly following a $191.3 million non-cash impairment on its NARCAN franchise, attributed to increased competition and pricing pressure in the naloxone market, which also led to investor alerts and investigations into potential securities law violations. In September 2026, the company secured a $24 million contract modification for CYFENDUS® and repurchased $75 million in senior unsecured notes. Earlier, in May 2026, Emergent BioSolutions reported a surprise profit in its Q1 2026 earnings, surpassing estimates.